CNBX Pharmaceuticals Inc. financial data

Symbol
CNBX on OTC
Location
Bethesda, MD
Fiscal year end
31 August
Latest financial report
10-Q - Q4 2025 - 14 Jan 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 0.96% % -67%
Return On Equity 15% % -31%
Return On Assets -1591% % -115%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 870,768,095 shares 2699%
Common Stock, Shares, Outstanding 753,196,666 shares 2321%
Common Stock, Value, Issued $75,319 USD 2321%
Weighted Average Number of Shares Outstanding, Basic 732,857,211 shares 2256%
Weighted Average Number of Shares Outstanding, Diluted 732,857,211 shares 2256%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $0 USD -100%
Research and Development Expense $0 USD -100%
General and Administrative Expense $298,856 USD -26%
Operating Income (Loss) $298,856 USD 33%
Net Income (Loss) Attributable to Parent $393,343 USD 29%
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $7,703 USD -56%
Assets, Current $11,162 USD -50%
Property, Plant and Equipment, Net $0 USD
Assets $11,162 USD -50%
Liabilities, Current $2,584,133 USD 1.9%
Retained Earnings (Accumulated Deficit) $25,382,095 USD -1.6%
Stockholders' Equity Attributable to Parent $2,572,971 USD -2.3%
Liabilities and Equity $11,162 USD -50%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $47,408 USD -21%
Net Cash Provided by (Used in) Financing Activities $40,000 USD 33%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 1,800,000,000 shares 100%
Common Stock, Shares, Issued 753,196,666 shares 2321%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $7,408 USD 18%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7,703 USD -56%
Depreciation $0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $393,343 USD 29%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Additional Paid in Capital $22,733,805 USD 1.2%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%